Federal Trade Commission et al v. Vyera Pharmaceuticals, LLC et al

  1. August 18, 2020

    'Pharma Bro' Shkreli Suggests FTC Privacy Violation

    Martin Shkreli accused the Federal Trade Commission on Monday of "short-circuit[ing]" efforts to look for potential Privacy Act violations in the agency's bid to use his prison communications in the civil antitrust case alleging he monopolized sales of the antiparasitic drug Daraprim, which a judge refused to toss Tuesday. 

  2. August 13, 2020

    FTC Says Shkreli's Prison Calls With Attorneys Not Privileged

    Martin Shkreli's phone calls with lawyers over prison-monitored lines do not fall under attorney-client privilege because he knew authorities could listen in, the Federal Trade Commission told a New York federal judge presiding over his civil antitrust case Wednesday.

  3. July 28, 2020

    'Pharma Bro' Blasts FTC Monopoly Suit As Overreach

    Convicted drug industry executive Martin Shkreli has told a New York federal judge that the Federal Trade Commission went too far with an "unprecedented" suit claiming he monopolized a lifesaving drug by blocking generic rivals.

  4. July 07, 2020

    FTC Fights Shkreli's Bid To Duck Monopolization Case

    The Federal Trade Commission and a contingent of states have urged a New York federal court not to toss their suit accusing former pharmaceutical executive Martin Shkreli and a company he founded of monopolizing the market for a lifesaving drug used to treat parasitic infections.

  5. June 16, 2020

    'Pharma Bro' Shkreli Can't Delay Discovery In Antitrust Suit

    A New York federal judge has rejected a bid from Martin Shkreli, the incarcerated former pharmaceutical executive, and a company he founded to delay discovery in a monopolization case from state and federal enforcers over a lifesaving drug used to treat parasitic infections.

  6. June 08, 2020

    FTC, States Fight Shkreli Bid To Delay Antitrust Suit Discovery

    The Federal Trade Commission and a coalition of states have pushed back against a motion by "Pharma Bro" Martin Shkreli, Vyera Pharmaceuticals, and Phoenixus AG to delay discovery in an antitrust case against them, claiming the former executive and the companies he led failed to show good cause for doing so.

  7. May 26, 2020

    Shkreli, Vyera Look To Duck Monopolization Claims

    Martin Shkreli and a company that the incarcerated former pharmaceutical executive founded have urged a New York federal court to toss allegations from state and federal enforcers that they monopolized the market for a drug used to treat potentially fatal parasitic infections.

  8. April 14, 2020

    Calif., 5 Other States Join Antitrust Suit Against Shkreli

    Six more state attorneys general on Tuesday joined a suit launched by New York state and the Federal Trade Commission accusing incarcerated "pharma bro" Martin Shkreli and his company Vyera Pharmaceuticals of monopolizing the market for a drug used to treat potentially fatal parasitic infections.

  9. March 20, 2020

    Shkreli-Founded Co. Defends Its Handling Of Life-Saving Drug

    An attorney for Martin Shkreli-founded Vyera Pharmaceuticals on Friday pushed back against allegations by the Federal Trade Commission and New York state that it monopolized the market for a drug used to treat potentially fatal parasitic infections, saying the fact a generic version has been approved shows the claims are incorrect.

  10. March 18, 2020

    'Pharma Bro' Suit Proceeds By Phone As COVID-19 Spreads

    A New York federal judge agreed on Wednesday to let an upcoming hearing in the state attorney general and Federal Trade Commission's suit against Martin Shkreli be handled by phone, but denied Shkreli's request to postpone the hearing in light of COVID-19's spread.